EEG Awareness Weeks – What EEG can do for a trial

The Siesta Group announces the "EEG Awareness Weeks" (http://www.thesiestagroup.com/news-a-events/calender-of-events) from Jan 7 to Mar 31, 2013. During this time The Siesta Group’s CEO Georg Dorffner and CSO Peter Anderer will hold free webinars on the topic "What EEG can do for a trial". A free feasibility analysis concerning efforts and costs of including EEG in an early or late phase trial to address CNS efficacy or safety of a drug will be offered to all participants.

Interested persons can mark a date for the webinar:

• Thursday, Feb 14, 2013, 4pm GMT (11am EST)
• Friday, Mar 15, 2013, 3pm GMT (11am EDT)

The webinar is directed toward all clinical trial professionals who work on the development of CNS-active drugs and plan a new early or late phase clinical trial. Electroencephalography (EEG), including Event-Related Potentials (ERP), can be an objective endpoint of choice in many cases – this webinar will make clear why, when and with what benefit.

Contents:
• Main EEG paradigms and endpoints
• Brain disorders and drug action as seen in the EEG
• The key-lock principle
• PD/PK modeling with EEG
• EEG topographies
• How The Siesta Group can support clinical trial EEG

Every participant will be entitled to receive a free feasibility and cost analysis about including EEG in a mock or real sample trial. Including EEG can be much more cost-effective than expected.

Interested persons can contact info@thesiestagroup.com for securing their webinar date and/or their personal analysis.

The Siesta Group is a comprehensive service provider supporting the measurement of sleep, wakefulness and brain activity in clinical trials and research. This encompasses, among others, high quality services concerning polysomnography (PSG), pharmaco-electroencephalography (pharmaco-EEG) and event-related potentials (ERP). In a close cooperation with Philips-Respironics this also includes actigraphy. The Siesta Group’s services range from consultation, site selection, site training, centralized data scoring and analysis, data quality control, to device rentals.
Innovative software technology, secure data transfer, state-of-the-art scientific know-how and flexible processes, all compliant with ICH-GCP and other regulation, ensure the best possible endpoints in measuring sleep, wake and brain activity in a trial.
The Siesta Group is the developer of Somnolyzer 24x7, the world’s most reliable and valid tool for computer-assisted sleep scoring. For clinical and diagnostic purposes, Somnolyzer 24x7 is now owned and marketed by Philips-Respironics. The use of Somnolyzer and its related EEG analysis tools in a clinical trial ensures a quality of endpoints unsurpassed by other providers in the field.
For further information, please visit http://www.thesiestagroup.com

The Siesta Group Schlafanalyse GmbH
Mag. Katharina Glasner
Schlosshofer Strasse 11/3d floor
1210 Vienna
Austria

This release was published on openPR.